Skip to main content
Kieren Mather, MD, Endocrinology, Indianapolis, IN

KierenMatherMDFRCPC

Endocrinology • Indianapolis, IN

Diabetes, Lipid Metabolism

Associate Vice President Early Diabetes Research

Join to view full profile

Dr. Mather is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Mather's full profile

Already have an account?

  • Office

    975 W Walnut St
    Ib 424
    Indianapolis, IN 46202
    Phone+1 317-944-8660

Education & Training

  • University of Calgary Faculty of Medicine
    University of Calgary Faculty of MedicineClass of 1992

Certifications & Licensure

  • IN State Medical License
    IN State Medical License 1999 - 2025

Awards, Honors, & Recognition

  • Elected Member The American Society for Clinical Investigation, 2012

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Genetic Ancestry Markers and Difference in A1c Between African-American and White in the Diabetes Prevention Program  
    Steven Kahn, William C Knowler, Kieren J Mather, Jose C Florez, The Journal of Clinical Endocrinology and Metabolism
  • Combination GLP-1 and Insulin Treatment Fails to Alter Myocardial Fuel Selection Versus Insulin Alone in Type 2 Diabetes  
    Kieren J Mather, Mark A Green, The Journal of Clinical Endocrinology and Metabolism

Press Mentions

  • Type 2 Diabetes Medications Don’t Prevent the Disease in People with Prediabetes, Study Suggests
    Type 2 Diabetes Medications Don’t Prevent the Disease in People with Prediabetes, Study SuggestsJune 11th, 2019
  • Complication Rates Ramp up in Kids with T2D
    Complication Rates Ramp up in Kids with T2DJune 9th, 2019
  • Two RISE Clinical Trials in Youth and Adults with Impaired Glucose Tolerance or Newly Diagnosed Type 2 Diabetes Reveal Surprising Differences in Beta-Cell (Β-cell) Function During and After Treatment
    Two RISE Clinical Trials in Youth and Adults with Impaired Glucose Tolerance or Newly Diagnosed Type 2 Diabetes Reveal Surprising Differences in Beta-Cell (Β-cell) Function During and After TreatmentJune 9th, 2019
  • Join now to see all

Grant Support

  • Preservation Of Beta Cell Function In Prediabetes/Early Type 2 DiabetesNational Institute Of Diabetes And Digestive And Kidney Diseases2011
  • Preservation Of Beta Cell Function In Prediabetes Early Type 2 DiabetesNational Institute Of Diabetes And Digestive And Kidney Diseases2011
  • Modulation Of Human Myocardial Metabolism By GLP-1National Heart, Lung, And Blood Institute2010–2011
  • Repaglinide As A Viable Alternative To Pre-Meal Insulin In Cystic Fibrosis RENational Center For Research Resources2007–2008
  • Myocardial Substrate Selection And Switching In Lean And Obese HumansNational Center For Research Resources2007–2008
  • Dual Actions Of Insulin In The Regulation Of Endothelin Activity In Vivo In HNational Center For Research Resources2006–2008
  • Treating The Endothelium To Restore Insulin SensitivityNational Center For Research Resources2005–2008
  • Mechanism Of Hemodynamically Induced Glucose UptakeNational Center For Research Resources2004–2008
  • PET Approach To Measuring Human Myocardial MetabolismNational Institute Of Diabetes And Digestive And Kidney Diseases2005–2006
  • The Effects Of Olmesartan Medoxomil, Losartan Potassium, And Atenolol On InsuNational Center For Research Resources2005–2006
  • Role Of Hemodynamics In In Vivo Insulin ResistanceNational Institute Of Diabetes And Digestive And Kidney Diseases2003

Dr. Kieren Mather, Dr. Kieren Mather, MD, Dr. K Mather